[ad_1]
The Central City Hospital of Domodedovo, where the first doses arrived, reported that resident doctors interested in receiving the vaccine had to register in advance on a Russian government website and submit a negative Covid-19 test.
Russia was the first country to register a vaccine against Covid-19 in the world, in August. The announcement raised concern among scientists, among other reasons, over the announcement of phase 3 trials and simultaneous mass vaccination.
In recent weeks, laboratories such as Pfizer, Moderna and AstraZeneca, which is developing a vaccine in partnership with Oxford, published the results of the initial phase 3 on the effectiveness rate of their vaccines still in development. None have yet published a scientific study with the data.
Initial data released by the companies indicated the following efficacy rates for their vaccines in development; rates may still change:
The FDA, the US regulatory agency equivalent to Anvisa in Brazil, has already announced that any vaccine must demonstrate 50% effectiveness before being released in the United States.